PPARA and steatosis: The pan-PPAR agonist lanifibranor has been shown to effectively reduce the SAF-A score (part of the Steatosis, Activity, Fibrosis scoring system) in a phase 2b trial, encouraging studies on PPAR agonists [3,53].